Novartis issues warning for breast cancer drug Femara

Share this article:

Novartis last week issued a warning that its breast cancer drug, Femara (letrozole), has been associated with birth defects, a caution prompted by reports that the drug was being used to help a woman become pregnant.
Femara is approved for use only in postmenopausal women with breast cancer. But there is evidence some doctors have prescribed it as a fertility treatment because it suppresses estrogen and can promote ovulation.
Novartis is sending letters to fertility doctors worldwide to reiterate a warning that the drug should not be given to women who may be pregnant, a company spokeswoman said in published reports.
The FDA has not taken any action, but a spokeswoman told the Associated Press that the agency was reviewing the matter. Novartis reportedly plans to send a letter to U.S. fertility specialists in coming days.

Share this article:

Email Newsletters

More in Business Briefs

Researchers hit links for charity

The PMR Charities Golf Classic teed up more than $20,000 for St. Jude Children's Research Hospital.

FDA to review Neupogen biosimilar

Novartis subsidiary Sandoz announced Thursday that the FDA has agreed to review its filgrastim biosimilar which is already approved in 40 countries.

FDA approves a new painkiller

Targiniq ER combines the prescription opioid oxycodone and naloxone, which is often used to treat overdoses.